CDK4 and head and neck squamous cell carcinoma: Phase 1 and 2 trials established the safety of co-administering the selective CDK4/6 inhibitor palbociclib and cetuximab in patients with R/M HNSCC and showed an ORR of 19% in cetuximab-resistant patients and 39% in platinum-resistant patients (97, 98).